Garfeld Susan, Douglas Michael P, MacDonald Karen V, Marshall Deborah A, Phillips Kathryn A
GfK, 21 Cochituate Road Wayland, MA 01778, USA.
Department of Clinical Pharmacy, Center for Translational & Policy Research on Personalized Medicine (TRANSPERS), University of California at San Francisco, 3333 California St, Room 420, Box 0613 San Francisco, CA 94143 USA.
Per Med. 2015 Jan 1;12(1):13-22. doi: 10.2217/pme.14.74.
Knowledge of consumer perspectives of personalized medicine (PM) is limited. Our study assessed consumer perspectives of PM, with a focus on oncology care, to inform industry, clinician and payer stakeholders' programs and policy.
MATERIALS & METHODS: A nationally representative survey of 602 US consumers' ≥30 years old explored familiarity, perspectives and expected value of PM.
Most (73%) respondents have not heard of 'personalized medicine,' though after understanding the term most (95%) expect PM to have a positive beneft. Consumer's willingness to pay is associated with products' impact on survival, rather than predicting disease risk. If testing indicates consumers are not candidates for oncology therapies, most (84%) would seek a second opinion or want therapy anyway.
Understanding heterogeneity in consumer perspectives of PM can inform program and policy development.
消费者对个性化医疗（PM）的看法的相关知识有限。我们的研究评估了消费者对个性化医疗的看法，重点关注肿瘤护理，以为行业、临床医生和支付方利益相关者的项目及政策提供参考。
一项对602名30岁及以上美国消费者的全国代表性调查，探讨了对个性化医疗的熟悉程度、看法及预期价值。
大多数（73%）受访者未听说过“个性化医疗”，不过在理解该术语后，大多数（95%）预计个性化医疗会带来积极益处。消费者的支付意愿与产品对生存的影响相关，而非预测疾病风险。如果检测表明消费者不适合肿瘤治疗，大多数（84%）仍会寻求第二种意见或无论如何都希望接受治疗。
了解消费者对个性化医疗看法的异质性可为项目和政策制定提供参考。
